BofA Securities raised the price target for the Novavax Inc. (NASDAQ:NVAX) stock to ‘an Underperform’. The rating was released on May 20, 2023, according to finviz. We previously noted in another research note published on February 23, 2023 by B. Riley Securities that reiterated the stock to a Buy with a price target of $265 for NVAX stock. The research report from Jefferies has resumed the stock to Buy, with a price target set at $198. The stock was initiated by Cowen, who disclosed in a research note on January 21, 2023, to Outperform and set the price objective to $150.